Zydus Lifesciences Ltd Share Price
(ZYDUSLIFE)
₹888.05▲0.17%
as on 04:01PM, 29 Apr 2025
Zydus Lifesciences Performance
Day's Low
Day's High
₹877.05Day's Price Range₹894.8552 Week's Low
52 Week's High
₹79552-Week Price Range₹1,324.3
| Returns % | |
| 1 Month Return | + 1.2 % |
| 3 Month Return | -6.86 % |
| 1 Year Return | -6.87 % |
| Market Stats | |
| Previous Close | ₹886.55 |
| Open | ₹887.00 |
| Volume | 10.28L |
| Upper Circuit | ₹975.20 |
| Lower Circuit | ₹797.90 |
| Market Cap | ₹89,358.61Cr |
Zydus Lifesciences Fundamentals
P/E Ratio
19.72
PEG Ratio
1.26
Market Cap
₹89,358.61 Cr
P/B Ratio
6.43
EPS
38.31
Dividend Yield
0.3
Sector
Pharmaceuticals
ROE
23.45
Mutual Fund Holdings of Zydus Lifesciences
Zydus Lifesciences Analyst Rating
based on 32 analysts
50.00%
Buy
28.12%
Hold
21.88%
Sell
Based on 32 analysts offering long term price targets for Zydus Lifesciences. An average target of ₹1050.75
Source: S&P Global Market Intelligence
Zydus Lifesciences Share analysis
Zydus Lifesciences price forecast by 32 analysts
Upside of18.32%
High
₹1365
Target
₹1050.75
Low
₹794
Zydus Lifesciences target price ₹1050.75, a slight upside of 18.32% compared to current price of ₹888.05. According to 32 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences revenue growth forecast
Expected growth rate Q1, FY2027:30.62%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences EPS growth forecast
EPS estimate Q1, FY2027:15.17%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Zydus Lifesciences Ltd
Zydus Lifesciences Gains After USFDA Approval - 28 Apr, 2025
Zydus Lifesciences Ltd shares increased by 3.3% following a successful USFDA inspection of its API facility, which resulted in six minor observations, none related to data integrity. The company also plans to acquire an 85.6% stake in Amplitude Surgical SA.Zydus Lifesciences Faces Growth Challenges and FDA Observations - 26 Apr, 2025
Zydus Lifesciences reported strong revenue growth in 9MFY25 but faces headwinds and regulatory challenges, including six observations from the USFDA at its Gujarat API unit.Zydus MedTech Partners for TAVI Technology Commercialization - 21 Apr, 2025
Zydus Lifesciences' subsidiary, Zydus MedTech, has entered a strategic partnership with Braile Biomedica to exclusively commercialize Transcatheter Aortic Valve Implantation technology in India, Europe, and other markets.Zydus Lifesciences Navigates Patent Ruling and Expands Portfolio - 17 Apr, 2025
Zydus Lifesciences faces a US court ruling on Myrbetriq patents but continues sales. The company also moves to acquire Amplitude Surgical shares and enters a TAVI licensing agreement, indicating growth potential despite challenges.Zydus Shares Plunge After Patent Case Loss - 16 Apr, 2025
Zydus Lifesciences shares dropped significantly after a US Federal Court ruled against them in a patent case involving Myrbetriq, potentially requiring market withdrawal and leading to financial penalties. The ruling is seen as a major setback for Zydus's US market ambitions.Zydus Lifesciences Gains FDA Approval and Acquires Amplitude - 15 Apr, 2025
Zydus Lifesciences announced the acquisition of 85.6% of Amplitude Surgical for Euro 256.8 million and received FDA approval for Jaythari tablets, boosting investor confidence and share price.Zydus Pharmaceuticals Issues Recall for Chlorpromazine Tablets - 13 Apr, 2025
Zydus Pharmaceuticals (USA) Inc is recalling 3,144 bottles of chlorproMAZINE Hydrochloride Tablets due to CGMP deviations and impurity concerns. The Class II recall was initiated on April 3, 2025.Zydus Secures USFDA Approval for Deflazacort Tablets - 12 Apr, 2025
Zydus Lifesciences has received USFDA approval for Jaythari (Deflazacort) tablets, a treatment for Duchenne muscular dystrophy. The company also reported a significant profit increase in Q3 FY25.Zydus Gains USFDA Approval and Expands in France - 11 Apr, 2025
Zydus Lifesciences received USFDA approval for Jaythari (Deflazacort) Tablets, enhancing its U.S. market presence. Additionally, it established a subsidiary in France to acquire Amplitude Surgical, marking a strategic expansion into orthopedics.Zydus Lifesciences Announces Rs 750 Crore Share Buyback - 10 Apr, 2025
Zydus Lifesciences has announced a Rs 750 crore share buyback offer, set to commence on June 23 and close on July 6, 2025. The buyback will involve over 1.15 crore shares, representing approximately 1.13% of the company's total paid-up equity share capital.Zydus Lifesciences Faces Stock Decline Amid News - 05 Apr, 2025
On April 5, 2025, Zydus Lifesciences' subsidiary Sentynl Therapeutics published clinical studies on NULIBRY. However, shares of Zydus and peers fell 3-6% during trading.Zydus Lifesciences Shares Plunge Amid Tariff Concerns - 04 Apr, 2025
Zydus Lifesciences shares fell nearly 7% following U.S. President Trump's comments on potential pharmaceutical tariffs, raising concerns over profitability and market dependence. Analysts warn of limited ability to pass on costs, increasing vulnerability to trade barriers.Zydus Lifesciences Shares Surge on Tariff Exemption - 03 Apr, 2025
Zydus Lifesciences shares rose 5.25% to ₹937.95 after the U.S. exempted pharmaceuticals from a 26% tariff on Indian goods, boosting investor confidence. Brokerages remain cautiously optimistic about the company's U.S. revenue potential, emphasizing the importance of tariff exemptions for maintaining margins.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 911.2 Cr → 1.02K Cr (in ₹), with an average increase of 11.0% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, ZYDUSLIFE stock has moved up by 4.0%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 6.32% to 6.36% in Mar 2025 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 5.30K Cr → 5.32K Cr (in ₹), with an average increase of 0.4% per quarter
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 74.98% to 74.99% in Mar 2025 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ZYDUSLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 59.0%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 7.53% to 7.32% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.84% to 6.68% in Mar 2025 quarter
Zydus Lifesciences Financials
Zydus Lifesciences Index Inclusions
Zydus Lifesciences Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.99% | 0.00 | |
| Foreign Institutions | 7.32% | 0.00 | |
| Mutual Funds | 6.36% | 0.00 | |
| Retail Investors | 6.68% | 0.00 | |
| Others | 4.65% | 0.00 |
Zydus Lifesciences Key Indicators
Zydus Lifesciences Valuation
Zydus Lifesciences in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (19.72x)
April 29, 2025
Industry (54.77x)
April 29, 2025
Highest (34.62x)
March 26, 2024
Zydus Lifesciences Earnings and Dividends
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit jumped 29.62% since last year same period to ₹1,023.50Cr in the Q3 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated 12.32% jump in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2024
In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 1.01%.
Read More about Dividends
Zydus Lifesciences Technicals Summary
Bearish
Neutral
Bullish
Zydus Lifesciences Ltd is currently in a Bearish trading position according to technical analysis indicators.
Zydus Lifesciences Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹89,358.61 Cr | 34.83% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹13,895.15 Cr | -4.49% | 0.52 | ₹413 Cr | ₹2,013 Cr | |
| BUY | ₹70,875.13 Cr | 18.65% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹63,962.50 Cr | 13.95% | 0.53 | NA | NA | |
| BUY | ₹49,165.02 Cr | 20.19% | 0.56 | ₹589 Cr | ₹3,453 Cr |
About Zydus Lifesciences
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Revenue: ₹5,123.50Cr as on December 2024 (Q4 24)
Net Profit: ₹1,004.30Cr as on December 2024 (Q4 24)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Zydus Lifesciences Ltd
What is Zydus Lifesciences Ltd price today?
Zydus Lifesciences Ltd share price today stands at ₹888.05, Open: ₹887, Previous Close: ₹886.55, High: ₹894.85, Low: ₹877.05, 52 Week High: ₹1324.3, 52 Week Low: ₹795.
How to Buy Zydus Lifesciences Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Zydus Lifesciences Ltd shares
What are today's traded volumes of Zydus Lifesciences Ltd?
Today's traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 10.28L.
What is today's market capitalisation of Zydus Lifesciences Ltd?
Today's market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹89358.61Cr.
What is the 52 Week High and Low Range of Zydus Lifesciences Ltd?
How much percentage Zydus Lifesciences Ltd is down from its 52 Week High?
Zydus Lifesciences Ltd (ZYDUSLIFE) share price is ₹888.05. It is down -32.94% from its 52 Week High price of ₹1324.3
How much percentage Zydus Lifesciences Ltd is up from its 52 Week low?
Zydus Lifesciences Ltd (ZYDUSLIFE) share price is ₹888.05. It is up 11.70% from its 52 Week Low price of ₹795